Literature DB >> 4790598

In vitro microassay for biological activity of cyclophosphamide metabolites.

D Laux, R N Lausch.   

Abstract

A rapid tissue culture assay for detecting the activated metabolites of cyclophosphamide in serum is described. Serum obtained shortly after drug administration was added to microtest wells containing a known number of previously planted target cells. The presence and amount of drug was directly correlated with the degree of inhibition of target cell replication. Either transformed or untransformed cells could be used as the target cells. No inhibition of cell growth was observed if cyclophosphamide was added directly to target cells without prior in vivo activation. The appearance and persistence of activated drug in hamster serum was followed by using in vitro microassay. Cyclophosphamide administered intraperitoneally was metabolized to its active form very rapidly, reaching peak activity in 15 min. After 2 h, activity was no longer detectable. Drug given subcutaneously was activated less rapidly and persisted for a longer period of time. The kinetics of drug activation, as determined by tissue culture assay, appeared to be similar to that obtained by chemical assay for other species.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4790598      PMCID: PMC444423          DOI: 10.1128/AAC.3.3.407

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Concomitant immunity in hamsters bearing syngeneic transplants of tumors induced by para-adenovirus 7, simian adenovirus 7, or 9,10-dimethylbenzanthracene.

Authors:  R N Lausch; F Rapp
Journal:  Int J Cancer       Date:  1971-03-15       Impact factor: 7.396

2.  Assay of cyclophosphamide.

Authors:  O D Boughton; R D Brown; R Bryant; F J Burger; C M Combs
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

3.  Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite.

Authors:  D L Hill; W R Laster; R F Struck
Journal:  Cancer Res       Date:  1972-04       Impact factor: 12.701

4.  Activation of cyclophosphamide in man and animals.

Authors:  N Brock; R Gross; H J Hohorst; H O Klein; B Schneider
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

5.  Urinary metabolites of the antitumor agent cyclophosphamide.

Authors:  R F Struck; M C Kirk; L B Mellett; S el Dareer; D L Hill
Journal:  Mol Pharmacol       Date:  1971-09       Impact factor: 4.436

6.  Duration of drug levels in mice as indicated by residual antileukemic efficacy.

Authors:  I Kline; M Gang; D D Tyrer; N Mantel; J M Venditti; A Goldin
Journal:  Chemotherapia (Basel)       Date:  1968

7.  A microassay for cell-mediated immunity.

Authors:  M Takasugi; E Klein
Journal:  Transplantation       Date:  1970-03       Impact factor: 4.939

8.  A simple micro tissue culture method for the dtermination of lymphocyte cytotoxicity in vitro.

Authors:  K Ulrich; J Kieler
Journal:  Proc Soc Exp Biol Med       Date:  1969-04

9.  Metabolism of cyclophosphamide.

Authors:  N Brock; H J Hohorst
Journal:  Cancer       Date:  1967-05       Impact factor: 6.860

10.  Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2.

Authors:  R Duff; F Rapp
Journal:  J Virol       Date:  1971-10       Impact factor: 5.103

View more
  1 in total

1.  Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models.

Authors:  Kiyomi Mashima; Iekuni Oh; Ken Fujiwara; Junko Izawa; Norihito Takayama; Hirofumi Nakano; Yasufumi Kawasaki; Daisuke Minakata; Ryoko Yamasaki; Kaoru Morita; Masahiro Ashizawa; Chihiro Yamamoto; Kaoru Hatano; Kazuya Sato; Ken Ohmine; Shin-Ichiro Fujiwara; Nobuhiko Ohno; Yoshinobu Kanda
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.